<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Sch of Medicine &amp; Dentistry</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CE97FC1C-8B83-431B-8DE7-749A3C4A5F95"><gtr:id>CE97FC1C-8B83-431B-8DE7-749A3C4A5F95</gtr:id><gtr:firstName>Bart</gtr:firstName><gtr:surname>Vanhaesebroeck</gtr:surname><gtr:orcidId>0000-0002-7074-3673</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E0678D24-9DCD-4BB2-B83F-B6C1260CCCCD"><gtr:id>E0678D24-9DCD-4BB2-B83F-B6C1260CCCCD</gtr:id><gtr:firstName>Pedro</gtr:firstName><gtr:otherNames>Rodriguez</gtr:otherNames><gtr:surname>Cutillas</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FG015023%2F1"><gtr:id>CCEC40D1-3F33-435B-BC83-B35F6CB3458B</gtr:id><gtr:title>In-depth quantification and characterisation of PI 3kinase signalling networks</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/G015023/1</gtr:grantReference><gtr:abstractText>We work on a group of signal transduction proteins called phosphoinositide 3-kinases (or PI3Ks in short) that play important roles in many biological functions in the healthy organism, and are also implicated in diseases such as diabetes, allergy, and cancer. There are 8 different PI3K genes and it is becoming clear that they have different functions and that they are involved in different diseases. The delineation of the roles of PI3K genes not only has purely academic importance in providing insight into fundamental biological processes but is also of huge interest for the ongoing development of drugs that inhibit specific forms of PI3Ks to treat different diseases. Despite many recent scientific advances in the field, there is little information on how the different forms of PI3K perform their distinct biological functions. The hypothesis we would like to test is that the different PI3Ks differ in the way by which they affect a group of proteins called protein kinases and their substrates. To test this hypothesis we will use a novel method that we have developed in the laboratory, based on a technique known as mass spectrometry, to quantify how active protein kinase pathways are in cells. The advantage of mass spectrometry is that it analyses the activities of protein kinases in a comprehensive fashion, allowing to quantify thousands of activities simultaneously. This depth of analysis is allowing us to quantify protein kinase activity without preconceptions of which of the many kinases in cells may or may not be affected by PI3K. It therefore also allows to discover unknown mechanisms of PI3K signal transduction. In the work proposed in this application we will inactivate the different PI3Ks in cells by pharmacological and genetic means, and compare to normal or untreated cells. The focus of this work will be on 3 different PI3Ks known as p110alpha, p110beta and p110delta. These results are likely to lead to the discovery of pathways specifically affected by the different PI3K genes. These results would be of high impact in the field and also allow to discover markers for drugs that inhibit these PI3Ks selectively. The second stage of the project involves investigating the role of these newly identified proteins as potential players in the function of PI3K, which will be achieved by standard genetic and biochemical approaches in cell-based studies.</gtr:abstractText><gtr:technicalSummary>This proposal offers a timely opportunity of combining unique expertise in analytical cell signalling and PI3K biology, now that the required technologies and genetic and pharmacological tools have matured to a level that can be used to start to address key questions in the field. There are 8 catalytic isoforms of PI3K and the creation of gene-targeted mice and pharmacological inhibitors with specificity for the different isoforms are contributing to the understanding of the biological functions of the different isoforms. Despite this information, little is known about the mechanisms by which distinct PI3K isoforms exert their non-redundant functions. The aim of this proposal is to investigate how inactivation of specific isoforms of the class IA subset of PI3Ks affects the activity of downstream protein kinases. For this, we will use a technique, based on mass spectrometry, for in-depth quantification of kinase activities. This method quantifies peptides bearing sites of phosphorylation. Our preliminary data indicate that it is possible to quantify thousands of phosphorylated sites with time frames compatible with the use of the technique as a 'routine' readout of biological experiments. Cells will be exposed to pan and isoform-selective PI3K inhibitors; phosphorylated sites will then be quantified with our techniques for in-depth analysis of kinase activities. Other experiments will involve comparing kinase activities in fibroblasts with genetic inactivation of Class IA PI3K isoforms with their wild-type counterparts. The second stage of the project involves validation of the mass spectrometry experiments using standard biochemical techniques and to address the role of selected novel PI3K pathway members in signalling and cell biology. These experiments are likely to provide novel information on how the PI3K pathway operates and could lead to the identification isoform-specific PI3K signalling pathways for the first time.</gtr:technicalSummary><gtr:fund><gtr:end>2012-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2009-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>331757</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>110000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Marie Curie Fellowship</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>PIIF-GA-2009-252846</gtr:fundingRef><gtr:id>26689A3B-FCBC-4D7D-80DC-B88BC12E0AA0</gtr:id><gtr:outcomeId>5ec6a3245ec6a338</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>490000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Barts Charity</gtr:fundingOrg><gtr:id>1132D508-0797-4822-B653-00B28798F2EB</gtr:id><gtr:outcomeId>545ccc232815d8.96650643</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Research from this laboratory resulted in the creation of a spin-out company that served the pharma and biotech sector, created jobs, and is now being used to identify biomarkers and drug targets of respiratory disease. This can benefit society in the future.</gtr:description><gtr:id>AFD871C6-7AE1-45C8-B965-D0C1FC1C917C</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>544a81a6f3fd94.26655681</gtr:outcomeId><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Methods to derive kinase activity data from phosphoproteomics experiments.</gtr:description><gtr:grantRef>BB/G015023/1</gtr:grantRef><gtr:id>F5E814EE-5A4A-46B1-B05E-88792D45D4D2</gtr:id><gtr:impact>The discovery is being evaluated in broader contexts than originally published as a means to infer the most appropriate targeted compound in individual cancer patients.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>544a51f9531033.08826513</gtr:outcomeId><gtr:patentId>PCT/EP2013/054764</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Kinase-substrate enrichment analysis</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Method for identifying proteotypic peptides</gtr:description><gtr:grantRef>BB/G015023/1</gtr:grantRef><gtr:id>75E857A7-E8C8-4782-AC75-C47E805141B8</gtr:id><gtr:impact>Licensed to Activiomics Ltd for 2 years, subsequently dropped.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>m-6568450132.9143077667ad00</gtr:outcomeId><gtr:patentId>PCT/GB2011/000586</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Method for identifying proteotypic peptides</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Method for identifying substrates of protein kinases (GKAP)</gtr:description><gtr:grantRef>BB/G015023/1</gtr:grantRef><gtr:id>D53C1D61-64A3-46AD-B8F0-0B2F4B1D0D38</gtr:id><gtr:impact>Licensed to Activiomics Ltd</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>m-1643282884.39967766893d2</gtr:outcomeId><gtr:patentId>PCT/GB2011/001497</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Method for identifying substrates of protein kinases</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Method for quantifying modified peptides (TIQUAS)</gtr:description><gtr:grantRef>BB/G015023/1</gtr:grantRef><gtr:id>617BF8E2-D851-4DC9-AC91-D35E9E864D1E</gtr:id><gtr:impact>This research output was licences to Activiomics Ltd, a spin out company from QMUL which was receently acquired by Retroscreen Virology Group.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>m-5906363600.7778017667abca</gtr:outcomeId><gtr:patentId>PCT/GB2010/000770</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Method for quantifying modified peptides</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>During this grant we developed and refined methodology to quantify kinase signalling. We used these methods to discover biochemical pathways downstream of an enzyme named phosphoinositide 3-kinase. We also discovered unexpected connections between different pathways in the biochemical network that regulates cell behaviour. The methodology created as part of this work was used to create a spin-out company.</gtr:description><gtr:exploitationPathways>The methods created as part of this work could be used by others to discover new drug targets and biomarkers for personalising therapies based on kinase inhibitors.</gtr:exploitationPathways><gtr:id>5D71402A-7BC5-4230-87E3-95C4006AAF59</gtr:id><gtr:outcomeId>56dbf54b358b54.98510842</gtr:outcomeId><gtr:sectors><gtr:sector>Digital/Communication/Information Technologies (including Software),Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>This is a method to quantify kinase activity from large phosphoprotemics data.</gtr:description><gtr:id>878BFFD0-B7CD-4C54-92D3-3CC67652D4F6</gtr:id><gtr:impact>The method, named KSEA, was published in 2013 (Casado et al Science Sig, PMID:23532336) and we have used it to discover new aspects of cells biology in our own research projects (e.g., Rajeeve et al 2014, PMID:24648465) as well as with collaborators (e.g., Herranz et al Nat Cell Biol 2015, PMID:26280535). We are also using KSEA with industrial partners (ProteomeSciences).</gtr:impact><gtr:outcomeId>56dbf0dbe7e599.14168753</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Computational method to quantify kinase activity</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>This is a method to quantify cell signalling based on the analysis of mass spectrometry data with software created specifically for this purpose.</gtr:description><gtr:id>3005F3E5-02B5-49E4-A9D2-D33264BF0D25</gtr:id><gtr:impact>The method was used as a core aspect of Activiomics, a spin-out company from QMUL. It is now licensed to hVivo.</gtr:impact><gtr:outcomeId>56dbeeb0d69c10.43510225</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Computational method to analyse mass spectrometry data</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>Pescal is a software to analyse mass spectrometry data.</gtr:description><gtr:id>534AF8BB-FEBB-4A50-92EC-D74D42DD5FFF</gtr:id><gtr:impact>This software was licensed to Activiomics Ltd, and was key in the business of the company.</gtr:impact><gtr:outcomeId>544a52f8069303.44346864</gtr:outcomeId><gtr:title>Pescal</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Activiomics Ltd</gtr:companyName><gtr:description>Activiomics Ltd is a privately owned spin-out company from the Barts Cancer Institute that uses mass spectrometry based technology developed, in part, with work from this award. The company currently employs three people full time and two part time. Activiomics offers mass spectrometry based services to the pharmaceutical and biotechnology industry, and so far it has had contracts from, among others, GSK, UCB and Genentech.</gtr:description><gtr:id>C94E2E01-945F-4D32-8B96-C0525BDB3F4C</gtr:id><gtr:impact>Activiomics successfully completed contract research with several biotech companies. Recently the company has been acquired by Retroscreen Virology Group for &amp;pound;4M and it now focuses on the identification of biomarkers and drug targets for respiratory disease.</gtr:impact><gtr:outcomeId>m-5873460477.1001835132ea036</gtr:outcomeId><gtr:url>http://www.activiomics.com/default.asp?id=1</gtr:url><gtr:yearCompanyFormed>2011</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>9E4462B0-45BB-40B5-9F1B-7B4FBC6E3156</gtr:id><gtr:title>Biological signalling activity measurements using mass spectrometry.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03b4f3ee6d24baa106aef76869ae301e"><gtr:id>03b4f3ee6d24baa106aef76869ae301e</gtr:id><gtr:otherNames>Cutillas PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>pm_53cc038c03846e86a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F532E7D7-E101-4BBF-9292-6C35700E60AA</gtr:id><gtr:title>Global profiling of protein kinase activities in cancer cells by mass spectrometry.</gtr:title><gtr:parentPublicationTitle>Journal of proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7a4b209002d9c580e741e913c93ef27"><gtr:id>d7a4b209002d9c580e741e913c93ef27</gtr:id><gtr:otherNames>Beltran L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1874-3919</gtr:issn><gtr:outcomeId>pm_5435aed5aedce0f4b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4315CDEA-806B-411E-A49E-7B3D41C8020C</gtr:id><gtr:title>Calpain interacts with class IA phosphoinositide 3-kinases regulating their stability and signaling activity.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7a4b209002d9c580e741e913c93ef27"><gtr:id>d7a4b209002d9c580e741e913c93ef27</gtr:id><gtr:otherNames>Beltran L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_5435aed5aedbab8e0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>870BB480-41C3-46BB-BF88-E3C28F2CC70D</gtr:id><gtr:title>Advances in phosphopeptide enrichment techniques for phosphoproteomics.</gtr:title><gtr:parentPublicationTitle>Amino acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7a4b209002d9c580e741e913c93ef27"><gtr:id>d7a4b209002d9c580e741e913c93ef27</gtr:id><gtr:otherNames>Beltran L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0939-4451</gtr:issn><gtr:outcomeId>pm_53cc040c04086036f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C465DEF-EF41-49E7-B228-58873312A7F8</gtr:id><gtr:title>Characterization of a TiO2 enrichment method for label-free quantitative phosphoproteomics.</gtr:title><gtr:parentPublicationTitle>Methods (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6884b61d279f8c13088c17cfb32c2bc"><gtr:id>e6884b61d279f8c13088c17cfb32c2bc</gtr:id><gtr:otherNames>Montoya A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1046-2023</gtr:issn><gtr:outcomeId>pm_5435aed5aedb05a00</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A9DD1DB-0D80-40FE-BCF2-282602D0AFA5</gtr:id><gtr:title>Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/841dce61efcbc8fb28a9397934215509"><gtr:id>841dce61efcbc8fb28a9397934215509</gtr:id><gtr:otherNames>Dermit M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>58b58df6b22720.01303032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5D08AA7-BD9B-4CBF-9100-96FCFC5A8324</gtr:id><gtr:title>Role of phosphoproteomics in the development of personalized cancer therapies.</gtr:title><gtr:parentPublicationTitle>Proteomics. Clinical applications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03b4f3ee6d24baa106aef76869ae301e"><gtr:id>03b4f3ee6d24baa106aef76869ae301e</gtr:id><gtr:otherNames>Cutillas PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1862-8346</gtr:issn><gtr:outcomeId>56db2f41d9f285.38098559</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>969A5528-8F6C-44A1-9704-B79B8C80D5A1</gtr:id><gtr:title>Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04ab8d573b12f52ecc1c48766b9f8100"><gtr:id>04ab8d573b12f52ecc1c48766b9f8100</gtr:id><gtr:otherNames>Casado P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>544a4b28a040f6.28577548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F050B706-D75F-490E-BE1F-5ABE5CE8D4E6</gtr:id><gtr:title>Current challenges in software solutions for mass spectrometry-based quantitative proteomics.</gtr:title><gtr:parentPublicationTitle>Amino acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3094b8c94e334addefedfef0d9296df"><gtr:id>e3094b8c94e334addefedfef0d9296df</gtr:id><gtr:otherNames>Cappadona S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0939-4451</gtr:issn><gtr:outcomeId>pm_53cc040c04092c89d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE1DCCC8-CB43-4683-83F9-14D593CB48D3</gtr:id><gtr:title>Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04ab8d573b12f52ecc1c48766b9f8100"><gtr:id>04ab8d573b12f52ecc1c48766b9f8100</gtr:id><gtr:otherNames>Casado P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn><gtr:outcomeId>544a4b28db6ab7.92901142</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B49BFD0-74B9-418C-9F23-73289C728C3C</gtr:id><gtr:title>Environmental stress affects the activity of metabolic and growth factor signaling networks and induces autophagy markers in MCF7 breast cancer cells.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04ab8d573b12f52ecc1c48766b9f8100"><gtr:id>04ab8d573b12f52ecc1c48766b9f8100</gtr:id><gtr:otherNames>Casado P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn><gtr:outcomeId>544a4bb0114355.10329523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63B1CC63-D080-4C4C-8AC3-F1A9E352920D</gtr:id><gtr:title>Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/efe96f4fdd8f749f95da88d18fd41b7f"><gtr:id>efe96f4fdd8f749f95da88d18fd41b7f</gtr:id><gtr:otherNames>Alcolea MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn><gtr:outcomeId>pm_5435aed5aeddf3e74</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6866CACB-4B46-4221-A899-97FE73A9DD8E</gtr:id><gtr:title>IMAC/TiO(2) enrich for peptide modifications other than phosphorylation: implications for chromatographic choice and database searching in phosphoproteomics.</gtr:title><gtr:parentPublicationTitle>Proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/131ac8e5a6865afe3f7b5de60b401d8e"><gtr:id>131ac8e5a6865afe3f7b5de60b401d8e</gtr:id><gtr:otherNames>Worthington J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1615-9853</gtr:issn><gtr:outcomeId>pm_5435aed5aedc4ce46</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/G015023/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>